NCT04366648View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 4, 2018

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions

Solid Tumor

Interventions

DRUG

JK-1201I

malignant solid tumor that has been confirmed by histopathology and/or cytology

Trial Locations (1)

100071

The fifth medical center of PLA general hospital, Beijing

All Listed Sponsors

lead

JenKem Technology Co., Ltd.

INDUSTRY

NCT04366648 - Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor | Biotech Hunter | Biotech Hunter